The role of sodium–glucose cotransporter 2 inhibitors (SLTG2i), developed initially as
glucose-lowering agents, has represented a novelty in patients with heart failure (HF) and …

Aims Current guidelines recommend that disease-modifying pharmacological therapies may
be considered for patients who have heart failure with mildly reduced ejection fraction …

Heart failure with preserved ejection fraction (HFpEF) accounts for more than half of heart
failure hospital admissions in the last years and is burdened by high mortality and poor …

Sodium–glucose cotransporter 2 inhibitors (SGLT2i), or gliflozins, have recently been shown
to reduce cardiovascular death and hospitalization in patients with heart failure …

In the primary care setting providers have more tools available than ever before to impact
positively obesity, diabetes, and their complications, such as renal and cardiac diseases. It is …

Diabetes mellitus (DM) represents a major public health problem, with yearly increasing
prevalence. DM is considered a progressive vascular disease that develops macro and …

Over the last three decades, several lifesaving therapies for the treatment of heart failure
with reduced ejection fraction (HFrEF) have emerged; however, this is not the case for heart …

Background The primary end point in most heart failure (HF) trials is a composite of time to a
first worsening HF event or cardiovascular death. Prevention of recurrent events and …

Introduction Heart failure (HF) is becoming a huge public health burden. New diabetes
drugs for type 2 diabetes (T2D), sodium-glucose cotransporter type 2 inhibitors (SGLT2is) …

The heart failure (HF) epidemic is one of the challenges that has been faced by the
healthcare system worldwide for almost 25 years. With an ageing world population and a …